NEW YORK – McGill University spinout Nplex is targeting an early 2021 launch for its highly multiplexed protein immunoassay system.
The company last week announced that it received a $1 million grant through the Canadian biopharma research consortium CQDM to fund development of the system, with McGill, the Québec government, and drugmaker GlaxoSmithKline funding the award. Nplex is also testing the system, which it calls nELISA, in work with GSK and the Montreal Neurological Institute.